Lasa Supergenerics Limited
₹25.75
INR-0.53(-2.02%)
As of November 14, 2024 10:00:00 AMAbout Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
RevenueLast 12 months
NA
+NA YoY
Total revenue generated from all business operations over the last 12 months
EBITDALast 12 months
NA
Earnings Before Interest, Taxes, Depreciation, and Amortization - a measure of company's operating performance
Price to Sales RatioTTM
1.25x
Compares a company's stock price to its revenues. Lower ratio might indicate an undervalued stock
Operating MarginLast 12 months
-3.23
+0% quarterly YoY
Operating income as a percentage of revenue, indicating operational efficiency
Market Cap
131.05 CrINR
Total market value of the company's outstanding shares
Employees
77
Total number of full-time employees worldwide
CEO
NA
Chief Executive Officer of the company